A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men.

Levels of a 90-kDa protein (90K), recently reported as a possible marker of HIV-1 infection, were serially examined in a group of HIV-1-infected (HIV-1+) and uninfected (HIV-1-) subjects drawn from the same cohort of homosexual men. The first phase of the study included 61 HIV-1+ AIDS-free subjects 4 years (+/- 6 months) postseroconversion and 75 contemporaneous unifected subjects. Two years later, a subset of 35 HIV-1+ AIDS-free subjects and 72 HIV-1- controls was examined. Mean 90K levels for HIV-1+ subjects were significantly higher than for contemporaneous HIV-1- subjects both 4 and 6 years postseroconversion (p < 0.0001). A significantly more rapid progression to AIDS was seen in HIV-1+ subjects with high 90K levels both 4 years (p = 0.01) and 6 years (p = 0.003) postseroconversion. Four years postseroconversion, 90K was significantly correlated with CD8 cell percent, interferon, neopterin, and beta 2-microglobulin (p < 0.05). Two years later, significant correlations were seen between 90K levels and CD4 cell percent, CD4 cell number, and beta 2-microglobulin (p < 0.05). Stepwise-stepdown regression modeling using 90K, CD4 cell percent, interferon, and beta 2-microglobulin levels 4 years postseroconversion showed that the predictive value of a trivariate model of 90K-interferon-CD4 percent was better than any univariate or bivariate model. We conclude that the 90K protein may be a useful predictor of progression to AIDS in HIV-1+ patients, particularly in combination with the established markers of CD4 cell percent and interferon.

[1]  S. Iacobelli,et al.  90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. , 1993, Journal of acquired immune deficiency syndromes.

[2]  N. Tinari,et al.  Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines , 1993, FEBS letters.

[3]  J. Goedert,et al.  Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. , 1992, American journal of epidemiology.

[4]  S. Iacobelli,et al.  Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. , 1991, The Journal of infectious diseases.

[5]  S. Iacobelli,et al.  Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. , 1991, The Journal of infectious diseases.

[6]  J. Goedert,et al.  Backcalculation of the number with human immunodeficiency virus infection in the United States. , 1991, American journal of epidemiology.

[7]  S. I. Kramer.  Book ReviewSexual Exploitation in Professional Relationships , 1990 .

[8]  S. Iacobelli,et al.  Recombinant alpha‐2b‐interferon enhances the circulating levels of a 90‐kilodalton (K) tumor‐associated antigen in patients with gynecologic and breast malignancies , 1990, Cancer.

[9]  R. Detels,et al.  Serum beta2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T‐cell fall and prognosis , 1990, AIDS.

[10]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[11]  E. Werner,et al.  Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. , 1989, Advances in clinical chemistry.

[12]  S. Iacobelli,et al.  Recombinant human leukocyte interferon‐α 2b stimulates the synthesis and release of a 90k tumor‐associated antigen in human breast cancer cells , 1988, International journal of cancer.

[13]  S. Iacobelli,et al.  Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. , 1988, Anticancer research.

[14]  J. Goedert,et al.  Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. , 1987, JAMA.

[15]  S. Iacobelli,et al.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. , 1986, Cancer research.

[16]  Susan E. Wilson,et al.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. , 1986, Science.

[17]  W. Woloszczuk.  A sensitive immunoradiometric assay for gamma interferon, suitable for its measurement in serum. , 1985, Clinical chemistry.

[18]  J. Goedert,et al.  DETERMINANTS OF RETROVIRUS (HTLV-III) ANTIBODY AND IMMUNODEFICIENCY CONDITIONS IN HOMOSEXUAL MEN , 1984, The Lancet.

[19]  E. Cooper,et al.  Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring. , 1980, British Journal of Cancer.

[20]  E. Cooper,et al.  Serum beta 2 microglobulin and C‐reactive protein in the monitoring of lymphomas findings in a multicenter study and experience in selected patients , 1980, Cancer.